| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 13 | 2026 | 222 | 3.170 |
Why?
|
| Reperfusion Injury | 7 | 2016 | 58 | 2.220 |
Why?
|
| Prostatic Neoplasms | 3 | 2026 | 504 | 2.020 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2026 | 175 | 1.810 |
Why?
|
| Liver Neoplasms | 10 | 2026 | 310 | 1.780 |
Why?
|
| Living Donors | 7 | 2025 | 78 | 1.410 |
Why?
|
| Liver | 8 | 2025 | 875 | 1.240 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 38 | 1.070 |
Why?
|
| Electroporation | 1 | 2026 | 36 | 0.940 |
Why?
|
| Single-Cell Analysis | 2 | 2026 | 119 | 0.940 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 9 | 0.930 |
Why?
|
| Oncolytic Viruses | 1 | 2025 | 10 | 0.930 |
Why?
|
| Multimodal Imaging | 1 | 2026 | 74 | 0.910 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2025 | 1 | 0.900 |
Why?
|
| Transaminases | 1 | 2025 | 15 | 0.890 |
Why?
|
| Positron-Emission Tomography | 1 | 2026 | 233 | 0.860 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2026 | 282 | 0.840 |
Why?
|
| Kidney | 4 | 2022 | 460 | 0.830 |
Why?
|
| Liver Diseases | 3 | 2024 | 157 | 0.770 |
Why?
|
| Vasodilation | 4 | 2014 | 36 | 0.750 |
Why?
|
| Lactobacillus | 1 | 2022 | 7 | 0.740 |
Why?
|
| Lactobacillales | 1 | 2022 | 5 | 0.740 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2022 | 5 | 0.730 |
Why?
|
| Fermentation | 1 | 2022 | 52 | 0.710 |
Why?
|
| Animals | 33 | 2025 | 21493 | 0.660 |
Why?
|
| Escherichia coli | 1 | 2025 | 718 | 0.650 |
Why?
|
| Male | 32 | 2026 | 31410 | 0.650 |
Why?
|
| End Stage Liver Disease | 2 | 2020 | 32 | 0.650 |
Why?
|
| Electronics | 2 | 2018 | 34 | 0.640 |
Why?
|
| Hepatic Artery | 1 | 2020 | 23 | 0.630 |
Why?
|
| Lipopolysaccharides | 4 | 2024 | 625 | 0.630 |
Why?
|
| RNA, Messenger | 3 | 2025 | 1583 | 0.620 |
Why?
|
| Membrane Proteins | 2 | 2023 | 926 | 0.610 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2019 | 2 | 0.590 |
Why?
|
| Computers | 1 | 2019 | 49 | 0.580 |
Why?
|
| Hepatectomy | 2 | 2025 | 63 | 0.540 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 240 | 0.540 |
Why?
|
| Mice | 17 | 2025 | 11185 | 0.530 |
Why?
|
| Nanoparticles | 1 | 2023 | 553 | 0.520 |
Why?
|
| Nitric Oxide | 4 | 2013 | 165 | 0.520 |
Why?
|
| NF-kappa B | 2 | 2016 | 436 | 0.510 |
Why?
|
| PPAR alpha | 1 | 2017 | 33 | 0.510 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 36 | 0.510 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 2329 | 0.500 |
Why?
|
| Endotoxemia | 1 | 2016 | 11 | 0.500 |
Why?
|
| Acetaminophen | 1 | 2017 | 53 | 0.500 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 53 | 0.490 |
Why?
|
| Protective Agents | 1 | 2016 | 12 | 0.490 |
Why?
|
| Biliary Atresia | 1 | 2016 | 2 | 0.490 |
Why?
|
| Rats | 11 | 2025 | 2005 | 0.490 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 27 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 2324 | 0.480 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2014 | 29 | 0.480 |
Why?
|
| Apoptosis | 4 | 2014 | 1100 | 0.470 |
Why?
|
| Body Weight | 2 | 2015 | 377 | 0.460 |
Why?
|
| Interferon-alpha | 2 | 2013 | 101 | 0.450 |
Why?
|
| Endothelium, Vascular | 4 | 2014 | 180 | 0.450 |
Why?
|
| alpha-Fetoproteins | 2 | 2014 | 14 | 0.450 |
Why?
|
| Natural Killer T-Cells | 1 | 2015 | 30 | 0.440 |
Why?
|
| Synapses | 1 | 2017 | 195 | 0.440 |
Why?
|
| Humans | 35 | 2026 | 65845 | 0.440 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 8 | 0.430 |
Why?
|
| Acidosis | 1 | 2014 | 28 | 0.430 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 143 | 0.420 |
Why?
|
| CA-19-9 Antigen | 1 | 2014 | 10 | 0.420 |
Why?
|
| Hepatocytes | 3 | 2024 | 226 | 0.410 |
Why?
|
| DNA | 3 | 2026 | 853 | 0.400 |
Why?
|
| Tissue Donors | 1 | 2014 | 147 | 0.400 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 141 | 0.390 |
Why?
|
| Recovery of Function | 1 | 2014 | 293 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 218 | 0.370 |
Why?
|
| Thymidine Phosphorylase | 1 | 2012 | 4 | 0.370 |
Why?
|
| Floxuridine | 1 | 2012 | 5 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2026 | 588 | 0.360 |
Why?
|
| Aorta, Thoracic | 3 | 2014 | 80 | 0.350 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 26 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2018 | 626 | 0.350 |
Why?
|
| Microbiota | 2 | 2025 | 171 | 0.350 |
Why?
|
| Mice, Inbred C57BL | 7 | 2022 | 3506 | 0.340 |
Why?
|
| Proteins | 2 | 2016 | 764 | 0.340 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 372 | 0.340 |
Why?
|
| Bacteria | 2 | 2025 | 337 | 0.340 |
Why?
|
| Mice, Knockout | 5 | 2017 | 2168 | 0.340 |
Why?
|
| Ischemic Postconditioning | 1 | 2010 | 3 | 0.330 |
Why?
|
| Thrombosis | 2 | 2026 | 207 | 0.330 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 11 | 0.330 |
Why?
|
| Triterpenes | 1 | 2010 | 7 | 0.330 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 220 | 0.320 |
Why?
|
| Kidney Diseases | 1 | 2012 | 178 | 0.320 |
Why?
|
| Brain | 1 | 2019 | 1672 | 0.310 |
Why?
|
| Treatment Outcome | 9 | 2026 | 5834 | 0.310 |
Why?
|
| Aorta | 2 | 2010 | 108 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 88 | 0.310 |
Why?
|
| Infant | 3 | 2020 | 1718 | 0.270 |
Why?
|
| rho-Associated Kinases | 1 | 2007 | 18 | 0.270 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2007 | 28 | 0.270 |
Why?
|
| Robotics | 2 | 2020 | 86 | 0.270 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 1573 | 0.260 |
Why?
|
| Tumor Microenvironment | 2 | 2026 | 183 | 0.260 |
Why?
|
| Oxidative Stress | 3 | 2017 | 323 | 0.260 |
Why?
|
| Child, Preschool | 3 | 2020 | 2090 | 0.260 |
Why?
|
| Amides | 1 | 2007 | 61 | 0.260 |
Why?
|
| Female | 19 | 2026 | 34425 | 0.260 |
Why?
|
| Niacinamide | 2 | 2018 | 33 | 0.250 |
Why?
|
| Phenylurea Compounds | 2 | 2018 | 32 | 0.250 |
Why?
|
| Pyridines | 1 | 2007 | 120 | 0.250 |
Why?
|
| Genistein | 1 | 2006 | 9 | 0.250 |
Why?
|
| Bufanolides | 1 | 2006 | 2 | 0.240 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2026 | 36 | 0.240 |
Why?
|
| Intraoperative Care | 1 | 2025 | 38 | 0.230 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 71 | 0.230 |
Why?
|
| Prostatic Hyperplasia | 1 | 2025 | 34 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 1 | 2025 | 85 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 420 | 0.220 |
Why?
|
| Saliva | 1 | 2025 | 100 | 0.220 |
Why?
|
| Time Factors | 5 | 2026 | 3779 | 0.220 |
Why?
|
| Oxalates | 1 | 2025 | 19 | 0.220 |
Why?
|
| Child | 4 | 2023 | 4653 | 0.220 |
Why?
|
| Middle Aged | 10 | 2026 | 18501 | 0.220 |
Why?
|
| Transfection | 3 | 2017 | 700 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 206 | 0.220 |
Why?
|
| Phenylenediamines | 1 | 2024 | 5 | 0.220 |
Why?
|
| Decidua | 1 | 2024 | 3 | 0.220 |
Why?
|
| Deferoxamine | 1 | 2024 | 5 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2026 | 3340 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2026 | 109 | 0.210 |
Why?
|
| Graft Rejection | 2 | 2017 | 304 | 0.210 |
Why?
|
| Hydrogels | 1 | 2026 | 127 | 0.210 |
Why?
|
| Biphenyl Compounds | 2 | 2015 | 29 | 0.210 |
Why?
|
| Stromal Cells | 1 | 2024 | 78 | 0.210 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2014 | 46 | 0.210 |
Why?
|
| Microcirculation | 2 | 2014 | 59 | 0.200 |
Why?
|
| Urinalysis | 1 | 2023 | 37 | 0.200 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 70 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 2 | 2014 | 140 | 0.200 |
Why?
|
| Ultrasonography | 1 | 2026 | 491 | 0.200 |
Why?
|
| Fibroblasts | 1 | 2026 | 423 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 245 | 0.200 |
Why?
|
| Cell Hypoxia | 3 | 2013 | 42 | 0.200 |
Why?
|
| Renal Circulation | 2 | 2013 | 15 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2018 | 605 | 0.190 |
Why?
|
| Signal Transduction | 5 | 2017 | 3170 | 0.190 |
Why?
|
| Aged | 5 | 2026 | 15147 | 0.190 |
Why?
|
| RNA Helicases | 1 | 2023 | 99 | 0.190 |
Why?
|
| Survival Rate | 3 | 2015 | 849 | 0.190 |
Why?
|
| Urinary Calculi | 1 | 2022 | 3 | 0.190 |
Why?
|
| Urolithiasis | 1 | 2022 | 5 | 0.180 |
Why?
|
| Ligands | 1 | 2023 | 414 | 0.180 |
Why?
|
| Concanavalin A | 1 | 2022 | 40 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 645 | 0.180 |
Why?
|
| Adolescent | 3 | 2020 | 6368 | 0.180 |
Why?
|
| Patient Safety | 1 | 2025 | 281 | 0.180 |
Why?
|
| Mutation | 3 | 2023 | 2675 | 0.180 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 238 | 0.180 |
Why?
|
| Constriction, Pathologic | 2 | 2020 | 131 | 0.180 |
Why?
|
| Transcriptome | 1 | 2026 | 408 | 0.180 |
Why?
|
| Follistatin-Related Proteins | 1 | 2022 | 22 | 0.180 |
Why?
|
| Anastomosis, Surgical | 2 | 2020 | 118 | 0.180 |
Why?
|
| Th17 Cells | 1 | 2022 | 65 | 0.180 |
Why?
|
| Glutamine | 1 | 2022 | 51 | 0.180 |
Why?
|
| Myocardium | 2 | 2017 | 302 | 0.180 |
Why?
|
| In Vitro Techniques | 4 | 2014 | 491 | 0.170 |
Why?
|
| China | 3 | 2018 | 181 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2020 | 6957 | 0.170 |
Why?
|
| DNA Helicases | 1 | 2023 | 202 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 133 | 0.170 |
Why?
|
| Exosomes | 1 | 2022 | 54 | 0.170 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1635 | 0.170 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 72 | 0.170 |
Why?
|
| Cell Membrane | 1 | 2023 | 506 | 0.170 |
Why?
|
| Antibody Formation | 1 | 2021 | 111 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 465 | 0.160 |
Why?
|
| Hypertension | 1 | 2006 | 618 | 0.160 |
Why?
|
| Leptin | 1 | 2021 | 89 | 0.160 |
Why?
|
| Methyltransferases | 1 | 2021 | 68 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 2021 | 115 | 0.160 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2020 | 8 | 0.160 |
Why?
|
| Mammals | 1 | 2022 | 222 | 0.160 |
Why?
|
| Kinetics | 1 | 2022 | 758 | 0.160 |
Why?
|
| Organ Size | 2 | 2023 | 175 | 0.160 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2020 | 16 | 0.160 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 34 | 0.160 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 369 | 0.160 |
Why?
|
| Neural Prostheses | 1 | 2020 | 1 | 0.160 |
Why?
|
| Microsurgery | 1 | 2020 | 55 | 0.160 |
Why?
|
| Afferent Pathways | 1 | 2020 | 16 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 100 | 0.160 |
Why?
|
| Gene Editing | 1 | 2024 | 331 | 0.150 |
Why?
|
| RNA Interference | 2 | 2013 | 647 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1226 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 809 | 0.150 |
Why?
|
| Iridoid Glycosides | 1 | 2018 | 1 | 0.140 |
Why?
|
| Gardenia | 1 | 2018 | 2 | 0.140 |
Why?
|
| Arthritis, Experimental | 1 | 2018 | 30 | 0.140 |
Why?
|
| Receptors, Artificial | 1 | 2018 | 2 | 0.140 |
Why?
|
| Adaptation, Biological | 1 | 2018 | 19 | 0.140 |
Why?
|
| Nociceptors | 1 | 2018 | 13 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 273 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2016 | 1561 | 0.130 |
Why?
|
| Oxygen | 3 | 2015 | 323 | 0.130 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2017 | 4 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2017 | 15 | 0.130 |
Why?
|
| Adult | 7 | 2018 | 17579 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 11 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1148 | 0.130 |
Why?
|
| Cytoprotection | 2 | 2015 | 18 | 0.130 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 80 | 0.130 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 755 | 0.130 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 6 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2015 | 1336 | 0.130 |
Why?
|
| Luciferases | 1 | 2017 | 107 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 382 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 34 | 0.130 |
Why?
|
| Galactosamine | 1 | 2016 | 1 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 183 | 0.120 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2014 | 10 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 131 | 0.120 |
Why?
|
| Postoperative Period | 2 | 2014 | 130 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 202 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 378 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2024 | 1044 | 0.120 |
Why?
|
| Phylogeny | 1 | 2018 | 400 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2024 | 852 | 0.120 |
Why?
|
| Genes, Reporter | 1 | 2017 | 257 | 0.120 |
Why?
|
| Geobacter | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cells, Cultured | 4 | 2017 | 2194 | 0.120 |
Why?
|
| Nanowires | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 54 | 0.120 |
Why?
|
| Electric Conductivity | 1 | 2016 | 52 | 0.120 |
Why?
|
| Liver Failure | 1 | 2016 | 18 | 0.120 |
Why?
|
| Acetylation | 1 | 2016 | 121 | 0.120 |
Why?
|
| Risk Factors | 3 | 2016 | 5475 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 51 | 0.120 |
Why?
|
| Integrases | 1 | 2016 | 41 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 142 | 0.120 |
Why?
|
| beta Catenin | 1 | 2016 | 100 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2500 | 0.120 |
Why?
|
| Bile Duct Diseases | 1 | 2015 | 10 | 0.120 |
Why?
|
| E2F1 Transcription Factor | 1 | 2015 | 18 | 0.120 |
Why?
|
| Bile Ducts | 1 | 2015 | 26 | 0.120 |
Why?
|
| Torsion Abnormality | 1 | 2015 | 12 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2022 | 714 | 0.110 |
Why?
|
| Graft Survival | 1 | 2016 | 300 | 0.110 |
Why?
|
| Carotenoids | 2 | 2018 | 68 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 134 | 0.110 |
Why?
|
| Ubiquitin | 1 | 2015 | 104 | 0.110 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2015 | 17 | 0.110 |
Why?
|
| Liver Failure, Acute | 1 | 2015 | 25 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2017 | 180 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 46 | 0.110 |
Why?
|
| Protein Binding | 2 | 2016 | 1638 | 0.110 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hydrochloric Acid | 1 | 2014 | 2 | 0.110 |
Why?
|
| Tracheophyta | 1 | 2014 | 1 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 171 | 0.110 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2016 | 263 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 81 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 117 | 0.100 |
Why?
|
| Perioperative Period | 1 | 2014 | 21 | 0.100 |
Why?
|
| Lamiaceae | 1 | 2014 | 1 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2014 | 108 | 0.100 |
Why?
|
| Flavonoids | 1 | 2014 | 57 | 0.100 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2014 | 144 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2013 | 29 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2013 | 3 | 0.100 |
Why?
|
| Nitric Oxide Donors | 1 | 2013 | 6 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2015 | 321 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 28 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 710 | 0.100 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 14 | 0.100 |
Why?
|
| Etoposide | 1 | 2013 | 34 | 0.100 |
Why?
|
| Hypoxia | 1 | 2014 | 121 | 0.100 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 28 | 0.100 |
Why?
|
| Thiazoles | 1 | 2013 | 45 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 61 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 413 | 0.100 |
Why?
|
| Flavones | 1 | 2014 | 53 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 44 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 134 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2014 | 199 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2016 | 352 | 0.090 |
Why?
|
| Lipocalins | 1 | 2012 | 4 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 23 | 0.090 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 3 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 746 | 0.090 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 35 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2012 | 23 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 196 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2014 | 414 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 932 | 0.090 |
Why?
|
| Indomethacin | 2 | 2014 | 23 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 216 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 97 | 0.090 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 64 | 0.090 |
Why?
|
| Incidence | 1 | 2015 | 1433 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 345 | 0.080 |
Why?
|
| DNA Damage | 1 | 2013 | 298 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1117 | 0.080 |
Why?
|
| Potassium Channel Blockers | 2 | 2010 | 23 | 0.080 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2010 | 1 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1439 | 0.080 |
Why?
|
| Ligation | 1 | 2010 | 37 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 83 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 690 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 65 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 344 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2013 | 423 | 0.080 |
Why?
|
| Mitochondria, Heart | 2 | 2014 | 14 | 0.070 |
Why?
|
| Models, Animal | 1 | 2010 | 243 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2013 | 719 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4883 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 799 | 0.070 |
Why?
|
| rhoC GTP-Binding Protein | 1 | 2007 | 3 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 27 | 0.070 |
Why?
|
| ras Proteins | 1 | 2007 | 76 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 527 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 2007 | 141 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 223 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 289 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2006 | 5 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2006 | 11 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2006 | 14 | 0.060 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 30 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 993 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2006 | 49 | 0.060 |
Why?
|
| Prognosis | 2 | 2026 | 1793 | 0.060 |
Why?
|
| Actins | 1 | 2007 | 265 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2006 | 22 | 0.060 |
Why?
|
| Pregnancy | 2 | 2024 | 2401 | 0.060 |
Why?
|
| Heat Shock Transcription Factors | 2 | 2016 | 12 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2025 | 47 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 107 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 1590 | 0.060 |
Why?
|
| Vitamin A | 2 | 2018 | 27 | 0.060 |
Why?
|
| Cyclohexylamines | 1 | 2024 | 4 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2024 | 23 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2025 | 75 | 0.050 |
Why?
|
| Heart Rate | 1 | 2006 | 335 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 30 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2026 | 301 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 869 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2025 | 262 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2015 | 287 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 297 | 0.050 |
Why?
|
| Tyrosinemias | 1 | 2024 | 20 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 18 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 537 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2023 | 20 | 0.050 |
Why?
|
| Iron | 1 | 2024 | 156 | 0.050 |
Why?
|
| KATP Channels | 1 | 2003 | 3 | 0.050 |
Why?
|
| RNA Recognition Motif Proteins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Death | 1 | 2023 | 33 | 0.050 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Hydrolases | 1 | 2024 | 84 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2023 | 47 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 182 | 0.050 |
Why?
|
| Cytoplasmic Granules | 1 | 2023 | 52 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2025 | 401 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 93 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 2 | 2014 | 45 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2015 | 216 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 123 | 0.050 |
Why?
|
| Plasmids | 1 | 2023 | 294 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2022 | 9 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2023 | 253 | 0.050 |
Why?
|
| Follistatin | 1 | 2022 | 44 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 73 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 93 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 162 | 0.040 |
Why?
|
| Immunization | 1 | 2021 | 135 | 0.040 |
Why?
|
| Adenosine | 1 | 2021 | 79 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2020 | 38 | 0.040 |
Why?
|
| Niobium | 1 | 2020 | 1 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 100 | 0.040 |
Why?
|
| Mechanoreceptors | 1 | 2020 | 13 | 0.040 |
Why?
|
| Oxides | 1 | 2020 | 36 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 59 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 329 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 541 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 455 | 0.040 |
Why?
|
| Iridoids | 1 | 2018 | 2 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 2018 | 14 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2021 | 213 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 184 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 374 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 383 | 0.030 |
Why?
|
| Livestock | 1 | 2018 | 1 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 61 | 0.030 |
Why?
|
| Vaccination | 1 | 2021 | 388 | 0.030 |
Why?
|
| Methicillin Resistance | 1 | 2018 | 23 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 95 | 0.030 |
Why?
|
| Diffusion | 1 | 2018 | 83 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 225 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2018 | 65 | 0.030 |
Why?
|
| Virulence | 1 | 2018 | 199 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2018 | 86 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 90 | 0.030 |
Why?
|
| Safety | 1 | 2018 | 142 | 0.030 |
Why?
|
| Cattle | 1 | 2018 | 320 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2018 | 208 | 0.030 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2017 | 35 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 47 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 129 | 0.030 |
Why?
|
| Biofilms | 1 | 2018 | 85 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2016 | 20 | 0.030 |
Why?
|
| Tryptophan | 1 | 2016 | 56 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2017 | 171 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 211 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 676 | 0.030 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1391 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 279 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 160 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 96 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 296 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2015 | 40 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 71 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 36 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1198 | 0.030 |
Why?
|
| Cholestasis | 1 | 2015 | 65 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2015 | 124 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 132 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 576 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 2014 | 19 | 0.030 |
Why?
|
| Testosterone | 1 | 2015 | 128 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2015 | 135 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 307 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 216 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2014 | 23 | 0.030 |
Why?
|
| DEAD Box Protein 58 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1266 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 39 | 0.030 |
Why?
|
| Heterografts | 1 | 2013 | 67 | 0.030 |
Why?
|
| Neuroglia | 1 | 2013 | 81 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2013 | 99 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 179 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 963 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 859 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 211 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 554 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 149 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 136 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 899 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 295 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2010 | 18 | 0.020 |
Why?
|
| Glucose | 1 | 2013 | 478 | 0.020 |
Why?
|
| Neurons | 1 | 2013 | 935 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 1503 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 241 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 121 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2003 | 267 | 0.010 |
Why?
|